Study title: AMPICILLIN/SULBACTAM VERSUS PLACEBO FOR THE INHIBITION OF PREMATURE LABOR OF PATIENTS ON TOCOLYSIS AND IN THE PROLONGATION OF THE LATENT PERIOD AFTER PREMATURE RUPTURE OF THE FETAL MEMBRANES
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Bacterial Infections and Mycoses [C01] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: SULBACTAM | |||||
ATC code: J01CG01 | |||||
Document link: | |||||
Document date: | |||||
Study number: R-0014* | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |